GSA Capital Partners’s Procept Biorobotics PRCT Stock Holding History

GSA Capital Partners’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.11M	Sell	49,269 -29,408	-37%	-$736K	0.07%	445
2026 Q1	$1.97M	Buy	78,677 +48,226	+158%	+$1.36M	0.12%	177
2025 Q4	$958K	Sell	30,451 -2,859	-9%	-$94.8K	0.08%	386
2025 Q3	$1.19M	Buy	33,310 +26,651	+400%	+$1.22M	0.1%	297
2025 Q2	$384K	Buy	+6,659	New	+$376K	0.03%	1109
2025 Q1	–	Sell	-3,364	Closed	-$271K	–	1993
2024 Q4	$271K	Buy	+3,364	New	+$287K	0.02%	1256
2024 Q3	–	Sell	-7,896	Closed	-$482K	–	1926
2024 Q2	$482K	Buy	+7,896	New	+$470K	0.03%	994
2023 Q2	–	Sell	-10,725	Closed	-$305K	–	1854
2023 Q1	$305K	Buy	+10,725	New	+$378K	0.03%	1019

Other funds holding PRCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

GSA Capital Partners's PRCT Position: Q2 2026 in Review

GSA Capital Partners reduced its Procept Biorobotics (PRCT) stake by 37% in Q2 2026, selling an estimated $736K and leaving 49,269 shares worth $1.11M. The position accounts for 0.07% of the portfolio, ranked #445.

GSA Capital Partners first reported a position in PRCT in Q1 2023 and has held it in 8 quarters since. The position peaked at $1.97M in Q1 2026. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

GSA Capital Partners held 49,269 shares of Procept Biorobotics worth $1.11M as of Q2 2026.
GSA Capital Partners sold 29,408 Procept Biorobotics shares in Q2 2026, an estimated $736K.
Procept Biorobotics made up 0.07% of GSA Capital Partners's portfolio in Q2 2026, its #445 holding.
GSA Capital Partners first reported a position in Procept Biorobotics in Q1 2023 and has held it in 8 quarters since.
GSA Capital Partners's Procept Biorobotics position peaked at $1.97M in Q1 2026.
254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.